Back to Results

Bioatla Inc (BCAB)

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing selective antibody-based therapeutics for solid tumor cancers. Its pipeline includes mecbotamab vedotin (BA3011), a conditionally active biologic antibody-drug conjugate being studied in undifferentiated pleomorphic sarcoma and non-small cell lung cancer, and ozuriftamab vedotin (BA3021), which is being developed for melanoma and squamous cell carcinoma of the head and neck. The company is also advancing Evalstotug (BA3071) for several tumor types, along with additional candidates such as BA3182, BA3361, BA3142, and a preclinical CAB-Nectin 4 x CAB-CD3 program. Founded in 2007, BioAtla is headquartered in San Diego, California. The company’s common stock is listed on NASDAQ under the ticker BCAB.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-BCAB
$2.46
41.8% Upside
Undervalued
$500 28,718.4% Upside
Not available
Bargain
Weak
0.0%
November 6, 2026
0.3x
2.891 M
7.21 M
67.0%
82.7%
-93.2
74.7%
Valuation • Fair Value

Bioatla Inc (NASDAQ-BCAB) Fair Value by Valuation Model

Review the available estimates for Bioatla Inc (NASDAQ-BCAB), including Comps Fair Value.

Primary Valuation Read

Fair Value

$2.46

Estimated upside of 41.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$2.46

Comparable-company valuation reference.

Analyst Price Target

$500 28,718.4% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Bioatla Inc (NASDAQ-BCAB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Bioatla Inc (NASDAQ-BCAB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

8.5 M

Current operating scale indicator.

Revenue Forecast

2 M

Forward revenue estimate.

EBITDA

-30.83 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Bioatla Inc (NASDAQ-BCAB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Bioatla Inc (NASDAQ-BCAB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-93.2

Lower score that deserves closer risk review.

FCF / Net Income

74.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Bioatla Inc (NASDAQ-BCAB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Bioatla Inc (NASDAQ-BCAB)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 6, 2026

Days to Earnings

68

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Bioatla Inc (NASDAQ-BCAB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Bioatla Inc (NASDAQ-BCAB) Stock Forecast & Technical Outlook

Review Bioatla Inc (NASDAQ-BCAB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Bioatla Inc (NASDAQ-BCAB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Bioatla Inc (NASDAQ-BCAB) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Bioatla Inc (NASDAQ-BCAB) Stock FAQ

Data-supported answers about Bioatla Inc (NASDAQ-BCAB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.46
Estimated upside 41.8%
Valuation Rating
Undervalued
Estimated upside of 41.8%
Analyst Target
$500 28,718.4% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Bioatla Inc (NASDAQ-BCAB) is $2.46. This implies an estimated upside of 41.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 41.8% versus the current market price.

The available analyst price target for Bioatla Inc (NASDAQ-BCAB) is $500 28,718.4% Upside.

The current financial health read for Bioatla Inc (NASDAQ-BCAB) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Bioatla Inc (NASDAQ-BCAB) is November 6, 2026.

The latest available data indicates no current dividend yield for Bioatla Inc (NASDAQ-BCAB).

The current market capitalization listed for Bioatla Inc is 2.891 M.

The current enterprise value listed for Bioatla Inc is 7.21 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Bioatla Inc is NASDAQ-BCAB, and the stock is listed on NASDAQ.

Bioatla Inc (NASDAQ-BCAB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Bioatla Inc is 67.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Bioatla Inc is 82.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B